SCHEMBL6791760

SCHEMBL6791760

O=C1NC(=O)C(CSCc2ccccc2)(C(O)c2ccc(-c3ccccc3)cc2)N1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 3/20 0.34
MMP9 P14780 3/20 0.34
MMP8 P22894 1/20 0.34
MMP3 P08254 2/20 0.34
ALDH1A1 P00352 2/20 0.33
ACP3 P15309 3/20 0.33
MMP13 P45452 3/20 0.32
MMP12 P39900 1/20 0.32
CYP2C19 P33261 1/20 0.32
PPARA Q07869 1/20 0.32
MMP1 P03956 1/20 0.32
MMP7 P09237 1/20 0.32
ACE P12821 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
CHRNB2 P17787 1/20 0.31
CHRNA4 P43681 1/20 0.31
DAO P14920 1/20 0.31
CRBN Q96SW2 1/20 0.31
ADAMTS5 Q9UNA0 1/20 0.31
CACNA1F O60840 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6799515 0.84 MMP2 (0.39) MMP2MMP9MMP8MMP3ALDH1A1
SCHEMBL6839920 0.81 MMP2 (0.36) MMP2MMP9MMP8MMP3ALDH1A1
SCHEMBL6842461 0.81 MMP2 (0.40) MMP2MMP9MMP8MMP3ALDH1A1
SCHEMBL6841039 0.79 MMP2 (0.38) MMP2MMP9MMP8MMP3ALDH1A1
SCHEMBL11933939 0.77 ADAM17 (0.48) MMP2MMP9MMP8MMP3ALDH1A1
SCHEMBL8337447 0.77 ADAMTS5 (0.41) MMP2MMP9MMP8MMP3ACP3
SCHEMBL6787210 0.76 CYP3A4 (0.39) MMP2MMP9MMP8MMP3ALDH1A1
SCHEMBL6791637 0.76 ADAM17 (0.50) MMP2MMP9MMP8MMP3ACP3
SCHEMBL10021371 0.74 ALDH1A1 (0.43) MMP2MMP9MMP8ALDH1A1ACP3
SCHEMBL6841024 0.71 MMP2 (0.43) MMP2MMP9MMP8ALDH1A1ACP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040110809-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-06-10 US disclosed
EP-1370536-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
EP-1370538-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074752-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110809-A1 Metalloproteinase inhibitors MMP9, MMP2, MMP3 MMP2 2/4885MMP9 1/4885MMP8 19/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 MMP2 11/4885MMP9 8/4885MMP8 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.